NCT04603131View on ClinicalTrials.gov

Clinical Trial to Evaluate the Immunogenicity of Chikungunya Vaccine

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

April 17, 2017

Primary Completion Date

January 30, 2018

Study Completion Date

July 30, 2018

Conditions
Chikungunya
Interventions
BIOLOGICAL

Inactivated Chikungunya virus vaccine 20 mcg

3 doses of Inactivated Chikungunya virus vaccine (BBV87) administered intramuscularly on Day 0, 29 and 57

BIOLOGICAL

Inactivated Chikungunya virus vaccine 30 mcg

3 doses of Inactivated Chikungunya virus vaccine (BBV87) administered intramuscularly on Day 0, 29 and 57

BIOLOGICAL

Inactivated Chikungunya virus vaccine 10 mcg

3 doses of Inactivated Chikungunya virus vaccine (BBV87) administered intramuscularly on Day 0, 29 and 57

BIOLOGICAL

Placebo

3 doses of Placebo administered intramuscularly on Day 0, 29 and 57

Trial Locations (4)

Unknown

King George Hospital, Visakhapatnam

Medanta - The Medicity, Gurgaon

KEM Hospital, Mumbai

Panchsheel Hospital, Delhi

All Listed Sponsors
lead

Bharat Biotech International Limited

INDUSTRY

NCT04603131 - Clinical Trial to Evaluate the Immunogenicity of Chikungunya Vaccine | Biotech Hunter | Biotech Hunter